Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1994 Feb;37(2):145–156. doi: 10.1111/j.1365-2125.1994.tb04254.x

Pharmacokinetic and -dynamic studies with a new anxiolytic, suriclone, utilizing EEG mapping and psychometry.

B Saletu 1, J Grünberger 1, L Linzmayer 1, H V Semlitsch 1, P Anderer 1, K Chwatal 1
PMCID: PMC1364591  PMID: 7910470

Abstract

1. In a double-blind, placebo-controlled, cross-over study, acute pharmacokinetic, neurophysiological and psychotropic effects of suriclone, a new cyclopyrrolone derivative, were investigated and compared with alprazolam. 2. Fifteen normal young volunteers received randomized oral single doses of placebo, 0.1, 0.2 and 0.4 mg suriclone as well as 1 mg alprazolam as reference compound. Investigations were carried out before and 1, 2, 4, 6 and 8 h after drug administration. 3. Pharmacokinetic investigations by radioimmunoassay showed a dose-dependent fast rise of plasma concentrations with a peak at 1 h and a rapid decline thereafter. Both the Cmax and the AUC values exhibited a linear relationship to dose. 4. EEG brain mapping demonstrated significant CNS effects of both compounds, characteristic for tranquillizers (increase of beta, decrease of alpha and increase of delta activity; attenuation of total power and acceleration of the centroid, i.e. centre of gravity frequency). When compared with alprazolam, suriclone exerted less sedative effects. 5. Time-efficacy calculations showed the pharmacodynamic peak effect of suriclone from the 2nd to the 4th hour, and of alprazolam in the 1st hour. Dose-efficacy calculations showed that the most pronounced CNS changes occurred after 1 mg alprazolam, followed by 0.4, 0.2 and 0.1 mg suriclone. 6. Psychometric investigations demonstrated no significant effects after the two lower doses of suriclone, while 0.4 mg and 1 mg alprazolam induced a decrement both in noopsychic and thymopsychic variables seen after higher doses of anxiolytic sedatives. Psychophysiology (critical flicker fusion, pupillometry, and skin conductance measures) pulse rate, systolic and diastolic blood pressure remained unchanged. 7. Psychophysiology (critical flicker fusion, pupillometry and skin conductance measures) showed differential dose-dependent effects. Pulse rate, systolic and diastolic blood pressure remained unchanged. Anxiolytic-characteristic side-effects (tiredness, drowsiness, etc.) occurred predominantly after the highest doses 0.4 mg suriclone and 1 mg alprazolam.

Full text

PDF
145

Images in this article

148Figure 2
on p.148
148Figure 3
on p.148
148Figure 4
on p.148
148Figure 5
on p.148

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen D., Lader M. The interactions of ethanol with single and repeated doses of suriclone and diazepam on physiological and psychomotor functions in normal subjects. Eur J Clin Pharmacol. 1992;42(5):499–505. doi: 10.1007/BF00314858. [DOI] [PubMed] [Google Scholar]
  2. Anderer P., Saletu B., Kinsperger K., Semlitsch H. Topographic brain mapping of EEG in neuropsychopharmacology--Part I. Methodological aspects. Methods Find Exp Clin Pharmacol. 1987 Jun;9(6):371–384. [PubMed] [Google Scholar]
  3. Anderer P., Semlitsch H. V., Saletu B., Barbanoj M. J. Artifact processing in topographic mapping of electroencephalographic activity in neuropsychopharmacology. Psychiatry Res. 1992 Aug;45(2):79–93. doi: 10.1016/0925-4927(92)90002-l. [DOI] [PubMed] [Google Scholar]
  4. Ansseau M., Olié J. P., von Frenckell R., Jourdain G., Stehle B., Guillet P. Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam, and placebo in generalized anxiety disorder. Psychopharmacology (Berl) 1991;104(4):439–443. doi: 10.1007/BF02245646. [DOI] [PubMed] [Google Scholar]
  5. Blanchard J. C., Zundel J. L., Julou L. Differences between cyclopyrrolones (suriclone and zopiclone) and benzodiazepine binding to rat hippocampus photolabelled membranes. Biochem Pharmacol. 1983 Dec 1;32(23):3651–3653. doi: 10.1016/0006-2952(83)90318-0. [DOI] [PubMed] [Google Scholar]
  6. Duffy F. H., Bartels P. H., Burchfiel J. L. Significance probability mapping: an aid in the topographic analysis of brain electrical activity. Electroencephalogr Clin Neurophysiol. 1981 May;51(5):455–462. doi: 10.1016/0013-4694(81)90221-2. [DOI] [PubMed] [Google Scholar]
  7. Gasser T., Bächer P., Möcks J. Transformations towards the normal distribution of broad band spectral parameters of the EEG. Electroencephalogr Clin Neurophysiol. 1982 Jan;53(1):119–124. doi: 10.1016/0013-4694(82)90112-2. [DOI] [PubMed] [Google Scholar]
  8. Gerlach J., Christensen J. K., Christensen T. L., Elley J., Jensen J. P., Larsen S. B. Suriclone and diazepam in the treatment of neurotic anxiety. A double-blind cross-over trial. Psychopharmacology (Berl) 1987;93(3):296–300. doi: 10.1007/BF00187246. [DOI] [PubMed] [Google Scholar]
  9. Gilburt S. J., Fairweather D. B., Kerr J. S., Hindmarch I. The effects of acute and repeated doses of suriclone on subjective sleep, psychomotor performance and cognitive function in young and elderly volunteers. Fundam Clin Pharmacol. 1992;6(6):251–258. doi: 10.1111/j.1472-8206.1992.tb00118.x. [DOI] [PubMed] [Google Scholar]
  10. Grünberger J., Linzmayer L., Saletu B. Klinische Psychodiagnostik mit Hilfe psychophysiologischer Verfahren. Wien Med Wochenschr. 1984 Jan 31;134(2):29–35. [PubMed] [Google Scholar]
  11. Grünberger J., Linzmayer L., Stöhr H., Wittek R., Saletu B. Computerunterstützte Rigiditätsmessung zur Differenzierung psychopathologischer Gruppen. Wien Med Wochenschr. 1988 May 15;138(9):206–212. [PubMed] [Google Scholar]
  12. Mason G., Rawlins M. D., Shuster S. Blood monocyte aryl hydrocarbon hydroxylase activity in psoriasis. Br J Clin Pharmacol. 1983 Sep;16(3):333–335. doi: 10.1111/j.1365-2125.1983.tb02170.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Saletu B., Anderer P., Kinsperger K., Grünberger J., Sieghart W. Comparative bioavailability studies with a new mixed-micelles solution of diazepam utilizing radioreceptor assay, psychometry and EEG brain mapping. Int Clin Psychopharmacol. 1988 Oct;3(4):287–323. doi: 10.1097/00004850-198810000-00002. [DOI] [PubMed] [Google Scholar]
  14. Saletu B., Anderer P., Kinsperger K., Grünberger J. Topographic brain mapping of EEG in neuropsychopharmacology--Part II. Clinical applications (pharmaco EEG imaging). Methods Find Exp Clin Pharmacol. 1987 Jun;9(6):385–408. [PubMed] [Google Scholar]
  15. Saletu B., Frey R., Grünberger J., Krupka M., Anderer P., Musch B. Sleep laboratory studies on single dose effects of suriclone. Br J Clin Pharmacol. 1990 Nov;30(5):703–710. doi: 10.1111/j.1365-2125.1990.tb03839.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Saletu B., Grünberger J., Linzmayer L., Flener R. Anxiolytics and beta blockers: evaluation of pharmacodynamics by quantitative EEG, psychometric and physiological variables. Agressologie. 1981 Oct;22(100):5–16. [PubMed] [Google Scholar]
  17. Saletu B., Grünberger J., Linzmayer L. On the central effects of a new partial benzodiazepine agonist Ro 16-6028 in man: pharmaco-EEG and psychometric studies. Int J Clin Pharmacol Ther Toxicol. 1989 Feb;27(2):51–65. [PubMed] [Google Scholar]
  18. Saletu B., Grünberger J., Linzmayer L. Pharmacokinetic and dynamic studies with a new anxiolytic imidazo-pyridine alpidem utilizing pharmaco-EEG and psychometry. Int Clin Psychopharmacol. 1986 Apr;1(2):145–164. doi: 10.1097/00004850-198604000-00006. [DOI] [PubMed] [Google Scholar]
  19. Saletu B., Grünberger J., Linzmayer L., Stadler R. Classification and assessment of cerebral bioavailability of lopirazepam (D-12524) by quantitative EEG and psychometric analysis. Arzneimittelforschung. 1980;30(3):513–518. [PubMed] [Google Scholar]
  20. Saletu B., Grünberger J., Sieghart W. Pharmaco-EEG, behavioural methods and blood levels in the comparison of temazepam and flunitrazepam. Acta Psychiatr Scand Suppl. 1986;332:67–94. doi: 10.1111/j.1600-0447.1986.tb08984.x. [DOI] [PubMed] [Google Scholar]
  21. Semlitsch H. V., Anderer P., Schuster P., Presslich O. A solution for reliable and valid reduction of ocular artifacts, applied to the P300 ERP. Psychophysiology. 1986 Nov;23(6):695–703. doi: 10.1111/j.1469-8986.1986.tb00696.x. [DOI] [PubMed] [Google Scholar]
  22. Shaw C. A., Sellers E. M., Sullivan J. T., Kaplan H. L. Comparative neurologic effects of diazepam and suriclone, a cyclopyrrolone anxiolytic. J Clin Psychopharmacol. 1988 Jun;8(3):189–192. [PubMed] [Google Scholar]
  23. Trifiletti R. R., Snyder S. H. Anxiolytic cyclopyrrolones zopiclone and suriclone bind to a novel site linked allosterically to benzodiazepine receptors. Mol Pharmacol. 1984 Nov;26(3):458–469. [PubMed] [Google Scholar]
  24. von Zerssen D., Koeller D. M., Rey E. R. Die Befindlichkeits-Skala (B-S)--ein einfaches Instrument zur Objektivierung von Befindlichkeitsstörungen, insbesondere im Rahmen von Längsschnittuntersuchungen. Arzneimittelforschung. 1970 Jul;20(7):915–918. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES